{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:02:43Z","timestamp":1792134163223,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy has shown to be efficacious in patients with deficient mismatch repair (dMMR)\/microsatellite instability-high (MSI-H) colorectal cancer (CRC). Unfortunately, there is still a population of patients who either do not respond or progress after prior response. Understanding the progression dynamics and outcomes based on the nature of disease progression (PD) is critical in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of 166 patients with advanced dMMR\/MSI-H CRC who received immunotherapy. PD patterns were classified as intrinsic (progression at first restaging scan) or adaptive (progression after initial stable\/responding disease) and as single organ or systemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Progression was seen in 64 patients (38.6%) with single organ progression in 31 (48.4%) and systemic progression in 33 (51.5%). Intrinsic progression was seen in 32 patients (50%) and adaptive progression in 32 (50%). Patients with single organ progression had a longer median TTP (mTTP) and median OS (mOS) compared to patients with systemic progression (mTTP: 8.8 vs 4.0\u2009months, P\u2009=\u2009.005; mOS: 65.9 vs 18.7\u2009months, P\u2009=\u2009.023). Patients with adaptive PD had a longer mTTP and mOS compared to patients with intrinsic PD (mTTP: 11.6 vs 1.9\u2009months, P = &amp;lt;.01; mOS: 65.9\u2009months vs 17.0\u2009months, P\u2009=\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis identifies significant differences in outcomes of patients with dMMR\/MSI-H CRC based on the pattern and extent of progression, underscoring the need for tailored therapeutic strategies depending on the nature of PD-1-based progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag235","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:40:57Z","timestamp":1784374857000},"source":"Crossref","is-referenced-by-count":1,"title":["Patterns of progression and survival in patients with mismatch repair deficient\/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-0561","authenticated-orcid":false,"given":"Michael","family":"LaPelusa","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preksha","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bhamidipati","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute , Nashville, TN 37203,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naishu","family":"Kui","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Bent","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9744","authenticated-orcid":false,"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Huey","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-2213","authenticated-orcid":false,"given":"Bryan","family":"Kee","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phat","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaysia","family":"Ludford","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Morelli","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-2252","authenticated-orcid":false,"given":"Van K","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-097X","authenticated-orcid":false,"given":"Christine","family":"Parseghian","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8238-8552","authenticated-orcid":false,"given":"Jason","family":"Willis","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-1610","authenticated-orcid":false,"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-9058","authenticated-orcid":false,"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-1142","authenticated-orcid":false,"given":"Victoria S","family":"Higbie","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072415414182800_oyag235-B1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026072415414182800_oyag235-B2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"key":"2026072415414182800_oyag235-B3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4161\/cbt.3.1.590","article-title":"Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer","volume":"3","author":"Arnold","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"2026072415414182800_oyag235-B4","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1053\/j.gastro.2012.09.032","article-title":"Epigenetics of colorectal cancer","volume":"143","author":"Goel","year":"2012","journal-title":"Gastroenterology"},{"key":"2026072415414182800_oyag235-B5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2026072415414182800_oyag235-B6","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2025.43.16_suppl.4019","article-title":"10-Year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)\/mismatch repair deficient (dMMR) advanced solid tumors","volume":"43","author":"Durham","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072415414182800_oyag235-B7","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1200\/JCO.2017.35.15_suppl.3071","article-title":"Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC","volume":"35","author":"Diaz","year":"2017","journal-title":"JCO"},{"key":"2026072415414182800_oyag235-B8","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2026072415414182800_oyag235-B9","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026072415414182800_oyag235-B10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"JCO"},{"key":"2026072415414182800_oyag235-B11","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"NEJM"},{"key":"2026072415414182800_oyag235-B12","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"2026072415414182800_oyag235-B13","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"2026072415414182800_oyag235-B14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br J Cancer"},{"key":"2026072415414182800_oyag235-B15","doi-asserted-by":"crossref","first-page":"117022","DOI":"10.1016\/j.bcp.2025.117022","article-title":"Targeting Werner helicase: a novel combination strategy for MSI colorectal cancer","volume":"239","author":"Peng","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"2026072415414182800_oyag235-B16","doi-asserted-by":"crossref","first-page":"113433","DOI":"10.1016\/j.ejca.2023.113433","article-title":"Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting","volume":"196","author":"Saberzadeh-Ardestani","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026072415414182800_oyag235-B17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann Oncol"},{"key":"2026072415414182800_oyag235-B18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.11.009","article-title":"Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"144","author":"Colle","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag235\/69571567\/oyag235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag235\/69571567\/oyag235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag235\/69571567\/oyag235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:41:51Z","timestamp":1784922111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag235\/8738354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag235","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,8]]},"article-number":"oyag235"}}